Startseite - Psoriasis-News

Pharmacological management of severe plaque psoriasis in patients with cancer
Pharmacological management of severe plaque psoriasis in patients with cancer

ein Artikel von Redaktion in PubMed
- vor 12 Stunden12 h
- 0 Antworten
IL-33 and Mast Cells in the Skin: From Molecular Mechanisms to Disease Implications
IL-33 and Mast Cells in the Skin: From Molecular Mechanisms to Disease Implications

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Supplement and fermented food use among older US adults with dermatologic disorders: A cross-sectional analysis
Supplement and fermented food use among older US adults with dermatologic disorders: A cross-sectional analysis

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis
Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality
Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Defining "Moderate" Psoriasis: A Targeted Review of the Medical Literature and Published Treatment Guidelines
Defining "Moderate" Psoriasis: A Targeted Review of the Medical Literature and Published Treatment Guidelines

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Successful long-term management of severe psoriasis with secukinumab after autologous hematopoietic stem cell transplantation for multiple myeloma: a case report
Successful long-term management of severe psoriasis with secukinumab after autologous hematopoietic stem cell transplantation for multiple myeloma: a case report

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Quinolinic acid as a central immunometabolic mediator of inflammation, neurodegeneration, and disease pathogenesis
Quinolinic acid as a central immunometabolic mediator of inflammation, neurodegeneration, and disease pathogenesis

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation
Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis
Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis

ein Artikel von Redaktion in PubMed
- Gestern 11:001 Tag
- 0 Antworten
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Mittwoch 00:002 Tage
- 0 Antworten
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1
OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Mittwoch 00:002 Tage
- 0 Antworten
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- Dienstag 00:003 Tage
- 0 Antworten
Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation
Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation

ein Artikel von Redaktion in PubMed
- Sonntag 11:005 Tage
- 0 Antworten
Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies
Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies

ein Artikel von Redaktion in PubMed
- Sonntag 11:005 Tage
- 0 Antworten
Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study
Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study

ein Artikel von Redaktion in PubMed
- Sonntag 11:005 Tage
- 0 Antworten
An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)
An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- 7. November7. Nov
- 0 Antworten
Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study
Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

ein Artikel von Redaktion in PubMed
- 6. November6. Nov
- 0 Antworten
Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial
Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial

ein Artikel von Redaktion in PubMed
- 6. November6. Nov
- 0 Antworten
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)
A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

ein Datensatz von Redaktion in Neu registrierte Studien in Deutschland
- 5. November5. Nov
- 0 Antworten

Letzte Aktivitäten

Pharmacological management of severe plaque psoriasis in patients with cancer

IL-33 and Mast Cells in the Skin: From Molecular Mechanisms to Disease Implications

Supplement and fermented food use among older US adults with dermatologic disorders: A cross-sectional analysis

Design, Synthesis, and Biological Evaluation of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Psoriasis

Model-Based Economic Evaluations of Interleukin Pathway Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Systematic Review of Model Structures, Assumptions, and Methodological Quality

Defining "Moderate" Psoriasis: A Targeted Review of the Medical Literature and Published Treatment Guidelines

Successful long-term management of severe psoriasis with secukinumab after autologous hematopoietic stem cell transplantation for multiple myeloma: a case report

Quinolinic acid as a central immunometabolic mediator of inflammation, neurodegeneration, and disease pathogenesis

Tofacitinib laden MCM-48 mesoporous silica nanogel for topical psoriasis: ex vivo and in vivo therapeutic validation

Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1

An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment

Keratinocyte FABP5 mediates saturated fat-induced MAPK/CCL20 signaling in psoriatic inflammation

Development of a tool to measure patient-oriented outcomes for Veterans with inflammatory arthritis initiating self-administered biologic therapies

Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study

An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy and Durability of Response to ESK-001 (ONWARD3)

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

Firearm Injury Prevention Bystander Intervention for Adolescents in Shooting Sports: A Cluster Randomized Clinical Trial

A multicenter, open-label, prospective study to assess the concentration of bimekizumab in mature breast milk from mothers receiving treatment with Bimzelx® (bimekizumab)

Konto

Navigation

Suche

Browser-Push-Nachrichten konfigurieren

Chrome (Android)

Chrome (Desktop)

Safari (iOS 16.4+)

Safari (macOS)

Edge (Android)

Edge (Desktop)

Firefox (Android)

Firefox (Desktop)